![Joseph Shulman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Joseph Shulman
Hoofd Techniek/Wetenschap/O&O bij
RHYTHM PHARMACEUTICALS, INC.
Vermogen: 2 M $ op 30-06-2026
Profiel
Joseph Shulman is Chief Technical Officer at Rhythm Pharmaceuticals, Inc. since 2022, with employment at the company starting in 2020.
Formerly, Mr. Shulman was Senior Vice President-Technical Operations at RA Pharmaceuticals, Inc. from 2019 to 2020 and Senior Vice President-Global Technical Operations at Novelion Therapeutics, Inc. from 2014 to 2019.
Education includes an MBA from Boston University and an undergraduate degree from the University of Miami.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 11-02-2026 | 18.970 ( 0,03% ) | 2 M $ | 30-06-2026 |
Actieve functies van Joseph Shulman
| Bedrijven | Functie | Begin |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 27-07-2020 |
Eerdere bekende functies van Joseph Shulman
| Bedrijven | Functie | Einde |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2020 |
| NOVELION THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2019 |
Opleiding van Joseph Shulman
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
29
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Rhythm Pharmaceuticals, Inc.
 Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Miami
 University of Miami Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Kies MarketScreener 
